Perkins Coie Represents BlackSwan Vascular in Strategic Investment by Sirtex Medical

PALO ALTO (December 18, 2020)—Perkins Coie is pleased to announce that it represented BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular embolization, in a Series B financing as part of a strategic investment by Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies.

Under the financing deal, Sirtex made a significant equity investment in exchange for preferred shares in BlackSwan in addition to an option to purchase the remaining shares of the company at an agreed price. Sirtex will also appoint an observer member to BlackSwan's Board of Directors.

The Perkins Coie deal team was led by Emerging Companies & Venture Capital group partner Adrian Rich and included associates Arian Galavis and Jessica North.

BlackSwan is a privately held company based in Hayward, California focused on the development of liquid embolic products tailored for use in peripheral vascular applications. The company was founded in 2017 by Suresh Pai and Celso Bagaoisan of LamaMed, LLC, a med-tech venture studio with a successful track record of capital-efficient product development from concept to commercialization, and Sanjay Shrivastava of U.S. Vascular, LLC, a privately held company engaged in developing and commercializing vascular medical devices.